Production (Stage)
Arrowhead Pharmaceuticals, Inc.
ARWR
$15.13
-$0.26-1.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 395.65% | -30.27% | -55.49% | -65.91% | -357.42% |
| Total Depreciation and Amortization | 34.45% | 22.80% | 30.22% | 45.97% | 69.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 51.81% | 34.13% | -3.68% | 12.93% | 4.74% |
| Change in Net Operating Assets | 1,251.69% | 31.57% | -86.47% | -55.93% | 103.15% |
| Cash from Operations | 598.02% | -24.13% | -429.26% | -455.51% | -191.68% |
| Capital Expenditure | 84.45% | 89.05% | 61.99% | 69.00% | -24.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -76.66% | -36.76% | -310.38% | -41.69% | -2,583.83% |
| Cash from Investing | -56.25% | 18.62% | -830.68% | 170.16% | -645.70% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -43.36% | 137.45% | -72.84% | -65.93% | 82,741.73% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -78.55% | 7,628.09% | 47,292.08% | 4,335.48% | 82,741.73% |
| Foreign Exchange rate Adjustments | -1,646.15% | -217.24% | 2,733.99% | -182.28% | 135.14% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 89.70% | 7.37% | 498.99% | -96.81% | 203.27% |